CSL Behring will continue to supply plasma-derived therapies to government after signing a new agreement with the National Blood Authority.
The authority, a federal government agency, coordinates arrangements for the supply of blood and blood products and services on behalf of all Australian governments.
According to health minister Greg Hunt, the new nine-year agreement provides government with savings of $200 million.
“CSL Behring welcomes the opportunity to continue our longstanding commitment to provide plasma-derived therapies to treat people in Australia with serious medical conditions including diseases of the immune system, disorders of blood clotting, or people who have been severely injured”, said general manager of CSL Behring Australia and New Zealand, Loretta Croker.
“The National Fractionation Agreement for Australia provides the healthcare system access to a secure supply of high-quality plasma-derived therapies for the duration of its nine-year term,” she said.
Under the new Agreement, CSL Behring will continue to supply plasma products manufactured at its advanced manufacturing facility located in the Melbourne suburb of Broadmeadows.
The plasma CSL Behring will use for supply under the National Fractionation Agreement for Australia is donated by Australia’s volunteer plasma donors, and collected by the Australian Red Cross Blood Service.